Regentis Biomaterials (NYSEAMERICAN:RGNT – Get Free Report) announced its earnings results on Friday. The company reported ($0.22) earnings per share (EPS) for the quarter, FiscalAI reports.
Regentis Biomaterials Trading Down 3.6%
RGNT stock opened at $1.89 on Friday. The company’s 50 day simple moving average is $2.22 and its 200-day simple moving average is $2.76. Regentis Biomaterials has a 12 month low of $1.23 and a 12 month high of $15.50.
Institutional Investors Weigh In On Regentis Biomaterials
An institutional investor recently bought a new position in Regentis Biomaterials stock. AIGH Capital Management LLC bought a new stake in shares of Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT – Free Report) during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned about 5.79% of Regentis Biomaterials as of its most recent filing with the SEC.
About Regentis Biomaterials
Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.
Further Reading
- Five stocks we like better than Regentis Biomaterials
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for Regentis Biomaterials Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regentis Biomaterials and related companies with MarketBeat.com's FREE daily email newsletter.
